登录 注册 会员服务 联系我们

Targeted Therapies: The Rare Cancer Paradigm

  • Published:2009-10-28 Issue:1 Volume:4 Page:19-37
  • ISSN:1574-7891
  • Container-title:Molecular Oncology
  • language:en
  • Short-container-title:

Author:

Pierotti Marco A.,Negri Tiziana,Tamborini Elena,Perrone Federica,Pricl Sabrina,Pilotti Silvana

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Reference103 articles.

1. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors);Alman;Am. J. Pathol,1997

2. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents;Argani;Am. J. Pathol,2001

3. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay;Argani;Am. J. Surg. Pathol,2003

4. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption;Aubin;Medscape Womens Health,2000 Mar

5. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma;Azizi;Lancet Oncol,2006
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3